4//SEC Filing
HAHN ELLIOT F 4
Accession 0001209191-12-003891
CIK 0001301081other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 5:11 PM ET
Size
22.9 KB
Accession
0001209191-12-003891
Insider Transaction Report
Form 4
Pharmasset IncVRUS
HAHN ELLIOT F
Director
Transactions
- Disposition from Tender
Common Stock
2012-01-12$137.00/sh−17,000$2,329,000→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−3,750→ 0 totalExercise: $10.10Exp: 2018-07-16→ Common Stock (3,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−20,000→ 0 totalExercise: $10.83Exp: 2019-10-14→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−15,000→ 0 totalExercise: $83.52Exp: 2021-10-11→ Common Stock (15,000 underlying) - Disposition from Tender
Common Stock
2012-01-12$137.00/sh−111,126$15,224,262→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−1.33→ 0 totalExercise: $2.01Exp: 2016-11-07→ Common Stock (1.33 underlying) - Disposition from Tender
Common Stock
2012-01-12$137.00/sh−111,122$15,223,714→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−40,000→ 0 totalExercise: $16.17Exp: 2020-10-14→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−10,000→ 0 totalExercise: $9.30Exp: 2018-10-29→ Common Stock (10,000 underlying)
Footnotes (9)
- [F1]Represents shares of time vesting restricted stock, reflecting the two-for-one stock split of the Issuer's common stock effective August 31, 2011 (the "Split"), which became unrestricted and eligible for tender pursuant to the Agreement and Plan of Merger between the Issuer and Gilead Sciences, Inc. (the "Merger Agreement").
- [F2]Represents shares owned by Elliot F. Hahn TTEE FBO Elliot F. Hahn Retained Annuity Trust 1, of which Mr. Hahn is the sole trustee.
- [F3]Represents shares owned by Elliot F. Hahn TTEE FBO Elliot F. Hahn Retained Annuity Trust 2, of which Mr. Hahn is the sole trustee.
- [F4]These options, which reflect the Split and which vested as to 25% on the date of grant (November 7, 2006), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $134.99 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F5]These options, which reflect the Split and which vested as to 25% on the date of grant (July 16, 2008), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.90 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F6]These options, which reflect the Split and which vested as to 25% on the date of grant (October 29, 2008), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $127.70 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F7]These options, which reflect the Split and which provided for vesting as to 25% on the date of grant (October 14, 2009), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.17 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F8]These options, which reflect the Split and which provided for vesting as to 25% on the date of grant (October 14, 2010), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $120.83 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F9]These options, which provided for vesting as to 25% on the date of grant (October 11, 2011), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $53.48 per share, representing the difference between the exercise price of the options and $137.00 per share.
Documents
Issuer
Pharmasset Inc
CIK 0001301081
Entity typeother
Related Parties
1- filerCIK 0001032729
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 5:11 PM ET
- Size
- 22.9 KB